FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy

Generic Coregs are coming

The FDA gave its blessing to more than a dozen generic versions of GlaxoSmithKline's Coreg (aka carvedilol), used to treat a variety of cardiovascular problems including high blood pressure and heart failure. Now, Glaxo will have to share the $1.7 billion carvedilol market with the likes of Actavis, Apotex, Caraco, Dr. Reddy's, Ranbaxy, Sandoz, Teva, and Watson, among others. A total of 14 generics were approved.

Ironically, the generic labeling may differ from the brand-name version because, while the drug itself is no longer under patent, certain bits of the labeling are. 

- see the FDA release

Related Articles:
Riled investors look for big changes at GSK. Report
Patent 'cliff' looms for Big Pharma. Report

More stories about Teva Pharmaceutical   Ranbaxy   Patent   GlaxoSmithKline   Generics   FDA approval   FDA   Coreg  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 4 + 73?
To combat spam, please solve the math question above.